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Clinical question: Is intravenous lipid emulsion a safe and effective therapy for the reversal 
and treatment of local anesthetic toxicity?
Results: Systematic reviews, human case reports, and experimental animal studies have demonstrated 
the efficacy of intravenous lipid emulsion therapy in successfully reversing cardiac arrhythmias, 
cardiac arrest, and cardiac collapse seen with severe systemic local anesthetic toxicity. There are 
fewer data to support treatment of neurologic toxicities associated with local anesthetics.
Implementation: Intravenous lipid emulsion 20% should be available whenever patients 
receive large doses of local anesthetics in operating rooms and emergency departments. Various 
dosing protocols have been published in the medical literature. Although the dosing protocols are 
based on low-level evidence, a lack of major adverse events makes lipid emulsion an appropriate 
therapy for treating cardiotoxic symptoms induced by local anesthetics.
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Intravenous lipid emulsion in local  
anesthetic toxicity
Definition: Local anesthetic overdose has been described as development of a variety 
of neurologic symptoms immediately following administration of local anesthetics. 
Symptoms are directly correlated with increasing local anesthetic blood concentra-
tions. Depending on severity of overdose, progression to seizure and/or coma, cardiac 
arrhythmias, cardiac arrest, cardiovascular collapse, and even death, can occur.
Incidence: The rate of severe overdose with local anesthetic agents is very low. It is 
estimated that severe toxicity occurs in 7.5 to 20 per 10,000 peripheral nerve blocks 
and approximately four of every 10,000 epidurals administered.1 Specific patient risk 
factors, concurrent medications, location and technique of block, specific anesthetic, 
and total dose, along with time to detection and appropriateness of treatment, all influ-
ence the likelihood and degree of systemic toxicity from local anesthesia.
Economics: No published study has addressed the economic issues of treatment for 
local anesthetic toxicity using rescue lipid emulsion. Economic issues include increased 
operating room time, increased hospital and intensive care length of stay, cost of lipid 
treatment, and disability and missed work days for affected individuals.
Level of evidence used: Systematic review and clinical practice guidelines.
Search sources: PubMed, Cochrane Library, EMBASE, International Pharmaceutical 
Abstracts and relevant citations from retrieved articles.
Outcomes: From the patient perspective, the main outcomes are:
1.  Effect on mortality
2.  Residual disease or disabilityTherapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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3.  Effective reversal of cardiovascular and neurologic 
symptoms.
Consumer summary: Toxicity from local anesthetics 
(commonly called “caine” anesthetics) can be severe, 
including seizures and cardiac arrest. A fat solution (lipid 
emulsion) given in the veins can help reduce the side effects 
and prevent death and disability.
The evidence
intravenous lipid emulsion infusion. Electrocardiographic 
abnormalities were also corrected, including asystole 
conversion, correction of torsades de pointes, and achievement 
of normal sinus rhythm from ventricular tachycardia. Men-
tal status improvements in both unpublished and published 
human case reports have been reported.
Clinical practice guidelines state that Intralipid® 20% has 
been shown to reverse cardiac arrest induced by local anesthetic 
in animal models and in human case reports, and its use has 
been reported in the treatment of life-threatening toxicity. It 
is recommended that intravenous lipid emulsion therapy be 
administered in all situations in which circulatory arrest attrib-
uted to local anesthetic toxicity is present, and considered in 
patients with cardiac symptoms other than cardiac arrest.3
Additional clinical practice recommendations cite lipid emul-
sion as a modality to mitigate cardiac toxicity seen with local 
anesthetic toxicity.4 Pancreatitis is a rare side effect associated 
with lipid emulsion therapy. However intravenous lipid emulsion-
induced pancreatitis is related to cumulative dosing and is seen 
with long-term repeated use in other disease states.
Conclusions
There is sufficient evidence to support the efficacy of intra-
venous lipid emulsion in the treatment of toxic overdose 
from local anesthetics and reversal of associated cardio-
vascular symptoms. Human data are limited for its use in 
managing neurotoxicity. Controversy concerning optimal 
dosing, therapy duration, and delay of administration still 
exists, and further study is warranted. Additional data 
focusing on adverse events and long-term effects are also 
necessary.
Does intravenous lipid emulsion 
infusion improve survival from local 
anesthetic toxicity?
Systematic reviews:    1
Clinical practice guidelines:  2
There are no randomized, controlled clinical trials evaluating 
management of systemic local anesthetic toxicity due to rarity 
of the event and difficulty in obtaining informed consent for 
experimental medical interventions in acute critical illness.
The systematic review found 39 case reports in humans 
with return of spontaneous circulation following infusion of 
lipid emulsion cardiac arrest associated with local anesthetic.2 
The review also cited a survival rate of 100% in a study of 
bupivacaine-induced cardiac arrest in dogs. Another study in 
rats showed a 30% increase in the lethal dose of bupivacaine 
administered after an intravenous lipid emulsion infusion. 
However, in a study of pigs receiving bupivacaine, there was 
a 100% return to spontaneous circulation in those treated 
with an epinephrine and vasopressin combination, but none 
in those treated with intravenous lipid emulsion.
is intravenous lipid emulsion effective in 
reversal of cardiovascular and neurologic 
symptoms associated with local 
anesthetic intoxication?
The systematic review concluded that there is convinc-
ing anecdotal and experimental evidence that intravenous 
lipid emulsion is effective in treating toxicity caused by local 
anesthetics.2 Normalization of heart rate, blood pressure, and 
correction of QRS widening were documented with post 
The practice
•	 Focus on airway maintenance (with endotracheal intuba-
tion if needed)
•	 Give 100% oxygen, and ensure adequate lung ventilation
•	 Intravenous access should be established
•	 Seizure control should be obtained with benzodiazepines
Assessment
•	 Local anesthetic induced toxicity can occur up to 
30 minutes following end of infusion
Potential pitfalls
Avoid vasopressin, calcium channel blockers, beta-blockers, 
or local anesthetics. In patients with cardiovascular 
instability, avoid propofol because of the potential for 
hypotension.
Management
•	 Stop local anesthetic administration
•	 Basic or advanced life support is essentialTherapeutics and Clinical Risk Management
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•	 Patients should be monitored closely throughout, 
including neurologic and cardiovascular assessment
•	 Neurologic signs may be subtle or absent, and include:
  Excitation (agitation, confusion, muscle twitching, seizure)
  Depression (drowsiness, obtundation, coma, apnea)
    Nonspecific (metallic taste, circumoral numbness, diplo-
pia, tinnitus, dizziness).
Severe  intoxication  is  most  often  indicated  by 
cardiovascular signs, including hyperdynamic signs and 
symptoms (hypertension, tachycardia, ventricular arrhyth-
mias) with progression to:
•	 Hypotension
•	 Conduction block, bradycardia, or asystole
•	 Ventricular arrhythmias
Treatment
Circulatory arrest
•	   Cardiopulmonary resuscitation and advanced cardiac life 
support, as indicated
•	 Manage arrhythmias (do not use lidocaine)
•	 Consider cardiopulmonary bypass in severe cases
Lipid emulsion efficacy may be reduced by high dose 
vasopressors5
Initial intravenous bolus injection of 20% lipid emulsion   
1.5 mL/kg over one minute and start an intravenous infusion 
of 20% lipid emulsion at 0.25 mL/kg/minute
•	   Lipid emulsion therapy administered via peripheral or 
central line
After five minutes, give two repeat boluses (maximum of 
three boluses) if cardiac stability has not been restored or 
adequate circulation deteriorates
•	   Leave five minutes between boluses
•	   Double infusion rate to 0.5 mL/kg/minute if no clinical 
improvement or deterioration occurs at any time
•	   Continue infusion until clinically stable and adequate 
circulation restored or maximum dose of lipid emulsion 
12 mL/kg has been administered
•	 Without circulatory arrest, use conventional therapy to 
treat hypotension, bradycardia, or tachyarrhythmia, and 
consider intravenous lipid emulsion therapy
•	 Monitor patients overnight for any signs of cardiac 
toxicity.
indications for specialist referral
•	 The acute nature of cardiac toxicity from local anesthetics 
complicates specialist referral and early treatment
•	 Once initial symptoms subside, patients should be moni-
tored by a cardiologist or intensivist
•	 Professionals with expertise in cardiopulmonary bypass 
should be consulted for severe cases.
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